Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ECOG-ACRIN Cancer Research Group
With
National Cancer Institute (NCI)
OBJECTIVES:
* To independently correlate the gene expression and promoter methylation profiles to chemotherapy response in patients with advanced or metastatic melanoma treated with carboplatin and paclitaxel with versus without sorafenib on clinical trial ECOG-E2603.
* To develop a predictive model of chemotherapy response utilizing integrated analysis of gene expression and promoter methylation data.
* To evaluate whether the NER pathway haplotypes are associated with platinum drug resistance and survival.
OUTLINE: This is a multicenter study.
Archived paraffin-embedded tissue samples are analyzed for gene expression and promoter methylation profiles, and genes involved in the NER pathway.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Diagnosis of melanoma
* Unresectable locally advanced or stage IV disease
Received carboplatin and paclitaxel with versus without sorafenib on clinical trial ECOG-E2603
Archived paraffin-embedded tissue samples
* Responder (complete or partial response, or stable disease) and non-responder (disease progression or unavailable)
PATIENT CHARACTERISTICS:
Not specified
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
Clareo Health | Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate
